$16.49
1.43% yesterday
NYSE, Sep 18, 10:10 pm CET
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Arcus Biosciences Stock price

$16.49
-0.82 4.74% 1M
-0.73 4.24% 6M
-2.61 13.66% YTD
-3.41 17.14% 1Y
-18.62 53.03% 3Y
+7.24 78.27% 5Y
-0.51 3.00% 10Y
NYSE, Closing price Wed, Sep 18 2024
-0.24 1.43%
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Key metrics

Market capitalization $1.51b
Enterprise Value $549.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.23
P/S ratio (TTM) P/S ratio 6.10
P/B ratio (TTM) P/B ratio 2.37
Revenue growth (TTM) Revenue growth 103.73%
Revenue (TTM) Revenue $247.00m
EBIT (operating result TTM) EBIT $-273.00m
Free Cash Flow (TTM) Free Cash Flow $-267.00m
Cash position $969.00m
EPS (TTM) EPS $-3.10
P/E forward negative
P/S forward 5.64
EV/Sales forward 2.11
Short interest 15.21%
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Arcus Biosciences forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Arcus Biosciences forecast:

Buy
80%
Hold
20%

Financial data from Arcus Biosciences

Assets
Dec '23
831 831
Cash 759 759
Claims 42 42
Inventories - -
Other current assets Other current assets Current assets 30 30
264 264
Property, plant and equipment 143 143
Financial assets 116 116
Intangible Assets - -
Other fixed assets Other assets Fixed assets 5 5
Total Assets 1,095 1,095
Liabilities
Dec '23
Equity 462 462
633 633
Current liabilities 184 184
Non-current liabilities 449 449
Total Capital 1,095 1,095

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Business Wire
8 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 27,800 shares of the Company's commo...
Neutral
Business Wire
23 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company's comm...
Neutral
Business Wire
28 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Wednesday...
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 577
Founded 2015
Website www.arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today